COMP <GO>
CYH vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Community Health Systems Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CYH 2
— JNJ 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $2.41 (-9.40%) • MKT CAP: $339.8M
balance-sheet
1.05
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.10% | 67.90% | +17.20 | CYH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.50% | 25.50% | -12.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.9x | 18.5x | -12.60 | CYH | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 11.90% | 34.70% | -22.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 4.10% | 28.50% | -24.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -1.20% | 6.00% | -7.20 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.05 | 5.59 | -4.54 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.1 | 62.1 | -32.96 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $339.8M | $662.49B | -$662.15B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYH REV | JNJ REV | CYH GROSS % | JNJ GROSS % | CYH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.48B | $94.19B | 85.1% | 67.9% | $208.0M | $19.70B |
| FY 2024 | $12.63B | $88.82B | 84.6% | 69.1% | $120.0M | $19.84B |
| FY 2023 | $12.49B | $85.16B | — | — | $210.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYH // BETA —
JNJ // BETA 1.08